Revolution Medicines Inc (NASDAQ: RVMD) kicked off on Monday, down -3.94% from the previous trading day, before settling in for the closing price of $38.62. Over the past 52 weeks, RVMD has traded in a range of $15.44-$41.21.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 11.11% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 19.05%. With a float of $137.20 million, this company’s outstanding shares have now reached $164.67 million.
In an organization with 378 employees, it is important to assess its efficiency.
Revolution Medicines Inc (RVMD) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Revolution Medicines Inc is 16.84%, while institutional ownership is 82.69%. The most recent insider transaction that took place on Jun 03 ’24, was worth 299,942. In this transaction an insider of this company sold 7,500 shares at a rate of $39.99, taking the stock ownership to the 322,322 shares. Before that another transaction happened on May 21 ’24, when Company’s General Counsel sold 1,500 for $39.11, making the entire transaction worth $58,671. This insider now owns 52,874 shares in total.
Revolution Medicines Inc (RVMD) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported -0.92 earnings per share (EPS), lower than consensus estimate (set at -0.82) by -0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.05% per share during the next fiscal year.
Revolution Medicines Inc (NASDAQ: RVMD) Trading Performance Indicators
Take a look at Revolution Medicines Inc’s (RVMD) current performance indicators. Last quarter, stock had a quick ratio of 18.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1339.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.76, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -3.51 in one year’s time.
Technical Analysis of Revolution Medicines Inc (RVMD)
Let’s dig in a bit further. During the last 5-days, its volume was 1.02 million. That was inferior than the volume of 1.31 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 28.81%. Additionally, its Average True Range was 1.53.
During the past 100 days, Revolution Medicines Inc’s (RVMD) raw stochastic average was set at 71.20%, which indicates a significant increase from 13.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.01% in the past 14 days, which was lower than the 40.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.86, while its 200-day Moving Average is $30.14. However, in the short run, Revolution Medicines Inc’s stock first resistance to watch stands at $38.22. Second resistance stands at $39.34. The third major resistance level sits at $40.21. If the price goes on to break the first support level at $36.23, it is likely to go to the next support level at $35.36. Assuming the price breaks the second support level, the third support level stands at $34.24.
Revolution Medicines Inc (NASDAQ: RVMD) Key Stats
The company with the Market Capitalisation of 6.12 billion has total of 164,986K Shares Outstanding. Its annual sales at the moment are 11,580 K in contrast with the sum of -436,370 K annual income. Company’s last quarter sales were recorded 740 K and last quarter income was -161,540 K.
